The lawsuit accuses the pharmaceutical company of discontinuing its widely used medication, Flovent, and replacing it with an identical product in an effort to avoid paying rebates to Medicaid due to the drug’s high price.
“GSK essentially just renamed Flovent,” the attorney general said in the lawsuit.
Ms. Mayes is seeking a declaration that the company violated the Arizona Consumer Fraud Act, which prohibits companies from selling a new drug at artificially inflated prices, and maximum statutory penalties of up to $10,000 per violation, according to Courthouse News Service.
Becker’s has reached out to GSK for comment and will update this article if more information becomes available.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.